Success Metrics

Clinical Success Rate
58.8%

Based on 10 completed trials

Completion Rate
59%(10/17)
Active Trials
2(7%)
Results Posted
40%(4 trials)
Terminated
7(23%)

Phase Distribution

Ph phase_3
6
20%
Ph early_phase_1
1
3%
Ph phase_2
10
33%
Ph phase_1
2
7%
Ph not_applicable
6
20%

Phase Distribution

3

Early Stage

10

Mid Stage

6

Late Stage

Phase Distribution25 total trials
Early Phase 1First-in-human
1(4.0%)
Phase 1Safety & dosage
2(8.0%)
Phase 2Efficacy & side effects
10(40.0%)
Phase 3Large-scale testing
6(24.0%)
N/ANon-phased studies
6(24.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

47.6%

10 of 21 finished

Non-Completion Rate

52.4%

11 ended early

Currently Active

2

trials recruiting

Total Trials

30

all time

Status Distribution
Active(2)
Completed(10)
Terminated(11)
Other(7)

Detailed Status

Completed10
Terminated7
unknown7
Withdrawn4
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
30
Active
2
Success Rate
58.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (4.0%)
Phase 12 (8.0%)
Phase 210 (40.0%)
Phase 36 (24.0%)
N/A6 (24.0%)

Trials by Status

withdrawn413%
completed1033%
active_not_recruiting13%
recruiting13%
terminated723%
unknown723%

Recent Activity

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT07567573

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

Completed
NCT01272037Phase 3

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Active Not Recruiting
NCT02420509

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

Terminated
NCT00875004Not Applicable

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

Terminated
NCT00881361Phase 2

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Completed
NCT01628211Phase 2

Second Look Laparoscopy in Colorectal Cancer

Unknown
NCT02773485Phase 3

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

Unknown
NCT00324727Phase 3

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Completed
NCT04769908Phase 2

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Unknown
NCT04170179Phase 2

Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis

Unknown
NCT04682249Phase 2

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Withdrawn
NCT04553458

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma

Completed
NCT00740961

Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer

Terminated
NCT04370925Phase 3

Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

Recruiting
NCT03398512Not Applicable

HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer

Terminated
NCT03349827Not Applicable

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Terminated
NCT02584556Phase 2

Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma

Withdrawn
NCT01233479Not Applicable

Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy

Withdrawn
NCT03822130Early Phase 1

Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer

Unknown
NCT01978249Not Applicable

A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis

Terminated

Drug Details

Intervention Type
PROCEDURE
Total Trials
30